---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013074"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:30.907776+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC

## Summary
- Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
- Estimated median OS of 17.8 months (95% CI lower bound 12.5 months), consistent with prior readout.
- 2 patients completed 33 cycles, suggesting extended dosing and tolerability for ateganosine.
- Phase 2 expansion trial began enrolling patients in July 2025 to further validate efficacy.

## SEC filing metadata
- accession: 0001493152-25-013074
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/0001493152-25-013074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225013074/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013074
- JSON: https://secwatch.observer/filing/0001493152-25-013074.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.